Dendreon Slams Shareholders' Bid To Stay $495M Sale
Bankrupt Dendreon Corp. tore into a request to stay its $495 million sale to Valeant Pharmaceuticals International Inc. pending an appeal, saying the shareholders' motion alleging a low valuation showed a...To view the full article, register now.
Already a subscriber? Click here to view full article